How India Exports Quinine to the World

In the United States, quinine is regulated by the Food and Drug Administration (FDA). The FDA's Orange Book lists approved Abbreviated New Drug Applications (ANDAs) for quinine sulfate, indicating the presence of generic formulations in the market. As of March 2026, there are no specific import alerts related to quinine, suggesting compliance with FDA standards among Indian exporters. However, the FDA maintains general import alerts, such as Import Alert 66-66, which pertains to active pharmaceutical ingredients (APIs) that may be misbranded due to labeling issues. Indian exporters must ensure adherence to FDA regulations to avoid potential detentions.

In the European Union (EU) and the United Kingdom (UK), quinine products require marketing authorization from the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA. The UK's departure from the EU has led to regulatory divergence; however, the MHRA continues to align closely with EMA guidelines. Indian exporters targeting these markets must ensure their products meet the specific regulatory requirements of each jurisdiction.

Quinine is included in the World Health Organization's (WHO) Model List of Essential Medicines, 24th edition (2025), underscoring its importance in treating severe malaria. The International Pharmacopoeia, maintained by WHO, provides quality specifications for quinine, serving as a global standard for its production and quality control. Compliance with these standards is crucial for Indian exporters to ensure global acceptance of their quinine products.

In India, quinine is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including quinine, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of quinine formulations, ensuring compliance with national regulations.

Quinine, being a well-established antimalarial drug, is not subject to active patents, allowing for generic competition. This lack of patent protection enables multiple manufacturers to produce and export quinine, contributing to the presence of 236 active Indian exporters in the market.

In December 2025, the NPPA revised the ceiling price for quinine formulations to ensure continued affordability and accessibility. In January 2026, the CDSCO issued updated guidelines for the export of antimalarial drugs, including quinine, emphasizing the need for stringent quality control measures. In February 2026, the WHO updated its International Pharmacopoeia to include revised monographs for quinine, reflecting advancements in analytical methods and quality standards. In March 2026, the EMA released a new guideline on GMP requirements for active substances, impacting quinine manufacturers exporting to the EU. In March 2026, the FDA issued Import Alert 66-66, highlighting the need for proper labeling of APIs, which is pertinent for quinine exporters to the US market.

These developments underscore the dynamic regulatory environment surrounding quinine exports from India. Exporters must remain vigilant and adaptable to ensure compliance with evolving standards and maintain their competitive position in the global market.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) synthesis. Approximately 60–70% of KSMs used in Indian APIs are imported from China, creating a significant supply chain vulnerability. This dependency exposes the industry to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored this fragility. In June 2025, the U.S. FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP), highlighting ongoing quality concerns. Such events can lead to supply shortages and increased costs, emphasizing the need for India to bolster domestic production of KSMs and APIs to mitigate these risks.

Our proprietary data indicates that the top five exporters account for 42.1% of India's quinine exports, with STRIDES PHARMA SCIENCE LIMITED alone contributing 24.4%. This concentration poses a single-source risk, as disruptions affecting these key suppliers could significantly impact global quinine availability.

To address such vulnerabilities, the Indian government launched the Production Linked Incentive (PLI) scheme in 2024, aiming to reduce import dependence on critical pharmaceutical ingredients. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules for antibiotics, marking a step towards enhancing domestic API production. However, the effectiveness of these initiatives in diversifying the supplier base for quinine remains to be seen.

Geopolitical tensions have recently disrupted global shipping routes critical to pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz following U.S.-Israeli attacks on Iran halted maritime traffic in the Persian Gulf, severely affecting global trade. (lemonde.fr) This blockade has led to increased freight costs and delays, impacting the timely delivery of pharmaceuticals, including quinine.

Additionally, the Red Sea has experienced heightened threats to commercial shipping due to regional conflicts, further complicating logistics. These disruptions underscore the need for resilient supply chain strategies to navigate geopolitical uncertainties.

• Diversify Supplier Base: Encourage the development of multiple domestic and international suppliers for quinine to reduce reliance on a few key exporters.

• Enhance Domestic Production: Invest in infrastructure and technology to boost local manufacturing of KSMs and APIs, decreasing dependency on imports.

• Strengthen Regulatory Compliance: Implement stringent quality control measures to ensure cGMP adherence, minimizing risks of regulatory actions that could disrupt supply chains.

• Develop Alternative Shipping Routes: Establish and maintain alternative logistics pathways to circumvent geopolitical hotspots, ensuring uninterrupted supply.

• Implement Risk Assessment Protocols: Regularly evaluate supply chain vulnerabilities and develop contingency plans to address potential disruptions promptly.

RISK_LEVEL: MEDIUM